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To introduce a new vision with an enhanced focus on the major factors 
contributing to pharmacokinetics and pharmacodynamics outputs at the 
level of both new drug introduction and clinical use of already 
appreciated medicines. Effect of enzymes, environment and genetic 
makeup on the pharmacology is discussed with a review of past focus 
by the scientists on such factors. The two terms are used for the first 
time solving the utmost problem in achieving therapeutic results by the 
scientists and patients. The meaning of two terms used in previous 
researches is illustrated briefly. People living in different countries 
experience different kinetic concentrations of medicines than literature 
value due to environment changes, enzyme variability and genetic  
transformations. Cmax, half-life, Vd, renal clearance and urinary excretion studies depicted 
marked variation due to change of enzyme and environmental factors among the individual of 
various origins and even among various individuals of same origin. For that two terms are 
coined pharmenzymonetics and pharmgeonetics. Advanced effects of medicine are 
entertained, enlightening cutting edge focus on the enzyme, environment and genetics prior 
study and treatment with a medicine to gain ideal or near to ideal therapeutic output. 
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INTRODUCTION 
Advanced therapies including chemotherapy, vaccination and other drug intake do not get 
100% therapeutic outcome in various individuals and even same species. Leaving behind the 
specie difference if we only see the human individuals there is a considerable difference in 
drug outcomes. When studied deeply the main factors which are notable include enzyme 
concentration changes due to change of environment and similarly genetic makeup which 
entertains the release of enzymes. Concentration change of enzyme puts fine change in the 
metabolism leading to change of whole therapeutic calendar of a medicine. A medicine 
approved for use in USA may not be used in Pakistan, Japan or Saudi Arabia with given dose 
and literature values. However serious eye on the pharmacological effect a medicine endorses 
needs to be kept where health condition of a whole country suffers. This is necessary to make 
kinetic and dynamic researches on the individual of those countries when only use of foreign 
manufacturer’s medicine is an option. In this paper the two terms are elaborated using 
tamoxifen antiestrogen drug as key model for proving the new coined terms however, other 
drugs are also mentioned where necessary. 
 
Pharmenzymonetics 
“ Pharmenzymonetics is the study of changed behavior of medicine in the living body due to 
enzyme and genetic makeup.” 
 
This term is thought to be responsible because multiple causes have been known to be 
involved in the metastatic breast cancer, but still chemotherapy is a question to absolutely 
treat this cancer (Shahbaz et al., 2014) and possibly this question arises because of 
genotypical and phenotypical change of metabolic enzymes in the body. An enzyme 
Debrisoquine hydroxylase (CYP2D6) is known to affect the disposition kinetics of a lot of 
clinical medicines where people of different region show variable capacity of CYP2D6 
substrate metabolism (Masimirembwa et al., 1996). In other cases the active site of the 
CYP2D6 is changed due to active medicament (Bapiro et al., 2002) and shows a metabolic 
correlation with the drug in different individuals where this study was done in Saudi Arabian 
people proving changed amount of enzymes in different people of different genetic makeup 
(McLellan et al., 1997). Similarly the CYP2D6 genotype is different in Japanese people and 
other African countries where one variant is at higher frequency as compared to the other 
variant (Nishida et al., 2000, Wennerholm et al., 2002). CY2D6 activity variation may be 
genetic or inhibited by other drug however, in breast cancer patients chemotherapeutic effect 
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of tamoxifen significantly decreased because being prodrug changed to its active metabolite 
after action of CYP2D6 (Siegelmann-Danieli et al., 2011) and also effects risperidone 
metabolism (Yagihashi et al., 2009). 
 
Many drugs show low bioavailability and other responses due to changed behavior of 
CYP3A4 substrates (Galetin et al., 2007, Maekawa et al.,2010 and Wang et al .,2011). Other 
CYP3A4 inducing agents such as rifampin highly decrease the concentration of toremifene 
and tamoxifen in the body and dose adjustment is required (Kivistö et al., 1998). Similarly 
the activity of CYP3A4 is regulated genetically (Angiolillo et al., 2006), same is true for 
other enzymes of P450 family that are controlled genetically and suggestd individual 
treatment plan (Ingelman-Sundberg., 2005) and CYP2C19 has shown to effect both 
pharmacokinetic and pharmacodynamic activites of certain drugs (Varenhorst et al.,2009). 
 
 
Fig 1. Diagramatic Illustration Of Effect Of Pharmenzymonetics And Pharmgeonetics 
On Drug Pharmacology. 
 
Now it is clear the activity of enzyme changes the pharmacokinetic parameters in the 
individuals and also metabolic enzymes like CYP2D6 are inherited as deficiency from 
parents to offspring (Bertilsson et al., 2002). Highly notable is when polymorphic genotype 
of CYP2D6 produces highest amount of N-Desmethyl tamoxifen (active metabolite) i-e. 
48.6±1.52pmol/20 min/pmol CYP (Boocock et al., 2002) while in other individuals this level 
is up to 40ng/mL which clarifies that the role of enzymes in the pharmacology is pivotal due 
to genetic variations. 
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Fig. 2. Directional visualization that depicts change of genetics among people leads to 
changed enzyme level or existence ultimately proves pharmenzymonetics. 
 
Few studies against Pharmenzymonetics 
Older few research works where enzyme induction or enzyme inhibition do not catch any 
effect on the pharmacokinetics values like plasma clearance, half-life and Vd of the labetolol 
and on heart rate and diastolic blood pressure of the same drug after oral and IM 
administration (Daneshmend et al., 1984). Hence it was just inhibition or induction of 
enzyme with no reference of genetic outputs without which the term pharmenzymonetics is 
incomplete and also, above study is obsolete and blurred due to its age as ozone layer has 
changed a lot since then. 
 
Pharmgeonetics 
“Pharmgeonetics is the study of changed effect of medicine in the living body due to change 
of environment and genetic makeup.” 
 
This term is also used partially as geonetics (Nawaz et al., 2008) which elaborates the effect 
of environment and genetic factors, yet here it is explained as the study of changed effect of 
medicine due to environment and genetic factors. It is because epigenetic factors are also 
responsible here. Broadly the environment may change the genetic factors of some 
individuals and their attitude towards medicine will be changed. The environment effect is 
less on microevolution( genetic) than on the phenotypic (plastic components) which may lead 
us to epigenetic factors, yet the global warming and ethnicity of decades have selected 
particular traits (Gienapp et al., 2008) which shows a promising alteration to medicine 
response. 
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Fig. 3. Cyclic representation of pharmgeonetics describing how change of environment 
alters epigenetics, which through microevolution leads to genetics variation (Richards. 
2006) and different etiology alters the pharmacology for particular medicine given in 
the same dose and direction as given in the literature. 
 
The disposition kinetics of kanamycin in mules (Muhammad et al., 2003) and 
sulfamethoxazole excretion in cows (Baig et al., 1998) after single IV dose is widely changed 
from literature value in Pakistan as these drugs are imported from other countries. Similarly 
pharmacokinetics and pharmacodynamics studies are being done in the largest universities of 
developed and developing countries on many drugs in relation to humans and animals and 
even among the individuals of same species to get the therapeutic benefit. 
 
Epigenetics are the key modulators pharmgeonetics providing evidences of changed drug 
response in various diseases both in animals and humans. The epigenetic studies is the key 
need of today to get the therapeutic outcomes of a drug or treatment. We are still working far 
away from the treatment standards and standard treatment guidelines.(Shahbaz et al., 2015) 
The tamoxifen has proved to be hepatocarcinogenic in rats and caused epigenetic factors thus 
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CONCLUSION 
The Pharmenzymonetics and pharmgeonetics are blocking the real effects of medicine in a 
hidden way and demands extensive research and study at subject level. There are drugs which 
are enzyme dependent and those enzymes vary in their concentration at cellular and organ 
level among individuals. Similarly the environment is effecting our drug action both 




New world is now related to individual treatment plans where enzyme levels, environmental 
and genetic factors are kept under minute consideration of experts hence pharmacists and 
pharmacologist have a leading pivotal role and position. The drugs which are imported need 
to be used only after clinical trial has been done with in that country on children, adults and 
aged. The enzyme tests where enzymes are controlled genetically should be taken. Here the 
position of clinical pharmacist at the serious level is mandatory rather than on paper work 
level to maintain a better healthier world. This (individual treatment plan) concept is started 
in a small but bigger task company at Islamabad named Perfect Health Pvt Ltd. 
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